- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03494985
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
August 29, 2018 updated by: GlaxoSmithKline
A Clinical Study to Evaluate the Efficacy of an Experimental Oralbalance Gel, Oral Rinse and Spray Versus Water
This study assessed the efficacy of three dry mouth products (including an experimental Oralbalance gel, oral rinse, and moisturizing spray) to relieve the feeling of dry mouth compared to water, in dry mouth population over a period of 28 days.
Study Overview
Status
Completed
Conditions
Detailed Description
This was a multi-centered (two-sites), examiner-blinded, four treatment arms, stratified (by Modified Dry Mouth Inventory [DMI] score), randomized, parallel group study in participants with self-reported dry mouth symptoms as determined by participant responses to the DMI.
Participants used their assigned dry mouth treatment at home for 28 days.
Study Type
Interventional
Enrollment (Actual)
422
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 84 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Understands and is willing, able and likely to comply with all study procedures and restrictions.
- Good general and mental health with, in the opinion of the investigator or medically qualified designee: a) No clinically significant and relevant abnormalities of medical history or oral examination., b) Absence of any condition that would impact on the subject's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements. Subjects with stable and controlled medical conditions with no overt medical conditions which would contraindicate participation (in the opinion of the Investigator or medically qualified designee) which would interfere with the conduct of the study.
- Self reported feeling of a dry mouth according to the modified DMI questions. Subject must answer at least 3 out of 5 questions with 'agree a little', 'agree' or 'strongly agree'.
Exclusion Criteria:
- Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- Women who are breast-feeding.
- Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
- Previous participation in this study.
- Recent history (within the last 1 year) of alcohol or other substance abuse.
- An employee of the sponsor or the study site or members of their immediate family.
- Subject works in one of the following: Advertising, Journalism, Public Relations, Manufacturing, retail or distribution of medicines, medical devices or healthcare products, Market Research or Marketing.
- Use of prescription systemic parasympathetic medications (e.g. Pilocarpine), for the treatment of the feeling of dry mouth.
- At the discretion of the examiner, subjects currently under the care of a dental/medical professional specifically for the treatment of dry mouth.
- Evidence of gross intra-oral neglect or need for extensive dental therapy.
- Denture wearer (partial or complete dentures).
- Subject with dental implants.
- Subjects with untreated oral mucosal disease which in the opinion of the investigator could interfere with the study (e.g. current oral ulceration).
- Subject is currently undergoing radiotherapy and/or chemotherapy treatment.
- Any condition the investigator identifies that can confound the subject's ability to properly participate in the study e.g. Alzheimer's Disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: OralBalance moisturizing gel
All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
|
Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue.
Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
|
EXPERIMENTAL: Oral rinse
All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
|
Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out.
Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
|
EXPERIMENTAL: Moisturizing mouth spray
All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
|
Participants sprayed one jet directly into their mouth.
Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
|
SHAM_COMPARATOR: Water only use
All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
|
Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use.
After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1: Relieving the Discomfort of Dry Mouth)
Time Frame: At Day 29 of treatment (2 hours after supervised product use)
|
Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQ I was assessed at 2 hours after supervised product use on Day 29 of treatment.
|
At Day 29 of treatment (2 hours after supervised product use)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1:Relieving the Discomfort of Dry Mouth ) at Day 29
Time Frame: At Day 29 of treatment (30 minutes, 1 hour and 4 hours after supervised product use)
|
Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product:1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQ I was assessed at 30 minutes, 1 hour, and 4 hours after supervised product use on Day 29 of treatment.
|
At Day 29 of treatment (30 minutes, 1 hour and 4 hours after supervised product use)
|
Modified Product Performance and Attributes Questionnaire I (PPAQ I) Question Number 1: Relieving the Discomfort of Dry Mouth) Day 1
Time Frame: At Day 1 of treatment (30 minutes, 1 hour, 2 and 4 hours after supervised product use)
|
Participants were asked to use the following scale to rate question 1 (Relieving the discomfort of dry mouth) of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 of treatment.
|
At Day 1 of treatment (30 minutes, 1 hour, 2 and 4 hours after supervised product use)
|
Individual Scores of All Question From 2-12 of Modified Product Performance and Attributes Questionnaire I (PPAQ I)
Time Frame: At Day 1 and 29 (30 minutes, 1 hour, 2 and 4 hours after supervised product use)
|
Participants were asked to use the following scale to rate question (Q) 2 to 12 of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQ I had following questions Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation.
PPAQ I was assessed at 30 minutes, 1 hour, 2, and 4 hours after supervised product use on Day 1 and 29 of treatment.
Individual score for each question at different tome point was reported for this endpoint.
|
At Day 1 and 29 (30 minutes, 1 hour, 2 and 4 hours after supervised product use)
|
Individual Scores for All Questions of Modified Product Performance and Attributes Questionnaire I (PPAQ I) at Day 8
Time Frame: At Day 8 (2 hours after supervised product use)
|
Participants were asked to use the following scale to rate questions of PPAQ I as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQI had following questions Q1: Relieving the discomfort of dry mouth Q2: Feeling comfortable in the mouth, Q3: Soothing your mouth, Q4: Allowing you to speak without difficulty, Q5: Effectively moistens your mouth, Q6: Effectively lubricates your mouth, Q7: Helping to freshen your breath, Q8: Protecting your mouth from drying out, Q9: Providing whole mouth comfort, Q10: Helping you to swallow without difficulty, Q11: Helping mouth feel 'normal', Q12: Having a cooling sensation.
PPAQ I was assessed at 2 hours after supervised product use on Day 8 of treatment.
|
At Day 8 (2 hours after supervised product use)
|
Individual Questions Scores of Modified Product Performance and Attributes Questionnaire II (PPAQ II)
Time Frame: At Day 8 and 29
|
Participants were asked to use the following scale to rate questions of PPAQ II as it applied to the study product: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
PPAQ II had following questions; Q1: Providing relief all night, Q2: Reducing the number of times you wake up from dry mouth, Q3: Feeling less parched when you wake up, Q4: Having a long lasting dry mouth relief, Q5.
Having a long lasting lubricating effect, Q6: Having a long lasting moisturizing effect.
PPAQ II was assessed before supervised product use on Day 8 and 29 of treatment.
|
At Day 8 and 29
|
Area Under Curve (AUC) up to 4 Hours After Treatment- Response of All Question of the Modified Product Performance and Attributes Questionnaire I (PPAQ I)
Time Frame: At Day 1 and 29
|
The AUC was calculated for the interval starting at the time of the 30 minute response and ending at the time of the last valid reading using the trapezoidal method on Day 1 and Day 29.
AUC was calculated for the score of the individual question of PPAQ1.
All the questions were scored using the following scale: 1= poor, 2= fair, 3= good, 4= very good, and 5= excellent.
|
At Day 1 and 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 17, 2013
Primary Completion (ACTUAL)
January 10, 2014
Study Completion (ACTUAL)
January 10, 2014
Study Registration Dates
First Submitted
April 5, 2018
First Submitted That Met QC Criteria
April 5, 2018
First Posted (ACTUAL)
April 11, 2018
Study Record Updates
Last Update Posted (ACTUAL)
September 26, 2018
Last Update Submitted That Met QC Criteria
August 29, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202902
- RH01986 (OTHER: GSK)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Xerostomia
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Cathrine RahbekDanish Cancer Society; DLHM - Danish Society for Mouth and Throat Cancer; Danish...Active, not recruitingXerostomia Following Radiotherapy | Xerostomia Following in Neck Ore Head After CancersurgeryDenmark
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Catholic University of the Sacred HeartSunstar Italiana SRL.CompletedXerostomia | Xerostomia Following RadiotherapyItaly
-
Qazvin University Of Medical SciencesImam Khomeini HospitalCompletedRadiation-Induced XerostomiaIran, Islamic Republic of
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
-
Institut de Terapia Regenerativa TissularUnknownXerostomia Due to RadiotherapySpain
Clinical Trials on Experimental Oralbalance Moisturizing Gel
-
Nova Scotia Health AuthorityDalhousie UniversityUnknownXerostomia | Hyposalivation
-
HAN Biomedical IncCompleted
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Thammasat University; Srinakharinwirot...CompletedHypertension | Diabetes Mellitus | XerostomiaThailand
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Thammasat University; Srinakharinwirot...CompletedCancer | Cancer of Head and Neck | Dry Mouth | Radiation-induced XerostomiaThailand
-
Dental Innovation Foundation Under Royal PatronageMahidol University; Ministry of Health, Thailand; Srinakharinwirot UniversityCompletedDry Mouth | Radiation-Induced Xerostomia | Cancer of Head NeckThailand
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedAtopic Dermatitis (AD)United States
-
Wake Forest University Health SciencesCompletedVentilator-associated PneumoniaUnited States
-
NovaBay Pharmaceuticals, Inc.CompletedImpetigoUnited States, South Africa
-
Vaginal Biome ScienceVaginal Biome ScienceCompletedBacterial VaginosisUnited States
-
Cosmetique Active InternationalCompleted